A Cell System for Phenotypic Screening of Modifiers of SMN2 Gene Expression and Function

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Li, Darrick K ^a,b   Tisdale, Sarah ^a,b   Espinoza Derout, Jorge ^a,b   Saieva, Luciano ^a,b   Lotti, Francesco ^a,b   Pellizzoni, Livio ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; SMALL NUCLEAR RIBONUCLEOPROTEIN; SURVIVAL MOTOR NEURON PROTEIN 2;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL PROLIFERATION; CELL STRAIN 3T3; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; ESSENTIAL GENE; FIBROBLAST; GENE DOSAGE; GENE EXPRESSION; GENE FUNCTION; GENE SILENCING; GENETIC SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN DEPLETION; RNA INTERFERENCE; SMN2 GENE; UPREGULATION;

ANIMALS; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; GENE ORDER; MICE; NIH 3T3 CELLS; PHENOTYPE; PROTEIN TRANSPORT; RNA INTERFERENCE; SURVIVAL OF MOTOR NEURON 2 PROTEIN;

EID: 84881559546     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071965     Document Type: Article

References (69)

1. Lunn MR, Wang CH, (2008) Spinal muscular atrophy. Lancet 371: 2120-2133.
2. Burghes AH, Beattie CE, (2009) Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nat Rev Neurosci 10: 597-609.
3. Monani UR, (2005) Spinal muscular atrophy: a deficiency in a ubiquitous protein; a motor neuron-specific disease. Neuron 48: 885-896.
4. Battle DJ, Kasim M, Yong J, Lotti F, Lau CK, et al. (2006) The SMN complex: an assembly machine for RNPs. Cold Spring Harb Symp Quant Biol 71: 313-320.
5. Neuenkirchen N, Chari A, Fischer U, (2008) Deciphering the assembly pathway of Sm-class U snRNPs. FEBS Lett 582: 1997-2003.
6. Pellizzoni L, (2007) Chaperoning ribonucleoprotein biogenesis in health and disease. EMBO Rep 8: 340-345.
7. Gabanella F, Butchbach ME, Saieva L, Carissimi C, Burghes AH, et al. (2007) Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PLoS One 2: e921.
8. Workman E, Saieva L, Carrel TL, Crawford TO, Liu D, et al. (2009) A SMN missense mutation complements SMN2 restoring snRNPs and rescuing SMA mice. Hum Mol Genet 18: 2215-2229.
9. Zhang Z, Lotti F, Dittmar K, Younis I, Wan L, et al. (2008) SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 133: 585-600.
10. Imlach WL, Beck ES, Choi BJ, Lotti F, Pellizzoni L, et al. (2012) SMN is required for sensory-motor circuit function in Drosophila. Cell 151: 427-439.
11. Lotti F, Imlach WL, Saieva L, Beck ES, Hao le T, et al. (2012) An SMN-dependent U12 splicing event essential for motor circuit function. Cell 151: 440-454.
12. Ruggiu M, McGovern VL, Lotti F, Saieva L, Li DK, et al. (2012) A role for SMN exon 7 splicing in the selective vulnerability of motor neurons in spinal muscular atrophy. Mol Cell Biol 32: 126-138.
13. Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, et al. (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80: 155-165.
14. Cartegni L, Krainer AR, (2002) Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat Genet 30: 377-384.
15. Kashima T, Manley JL, (2003) A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet 34: 460-463.
16. Lorson CL, Hahnen E, Androphy EJ, Wirth B, (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A 96: 6307-6311.
17. Pedrotti S, Bielli P, Paronetto MP, Ciccosanti F, Fimia GM, et al. (2010) The splicing regulator Sam68 binds to a novel exonic splicing silencer and functions in SMN2 alternative splicing in spinal muscular atrophy. EMBO J 29: 1235-1247.
18. Burnett BG, Munoz E, Tandon A, Kwon DY, Sumner CJ, et al. (2009) Regulation of SMN protein stability. Mol Cell Biol 29: 1107-1115.
19. Cho S, Dreyfuss G, (2010) A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. Genes Dev24: 438-442.
20. Lorson CL, Androphy EJ, (2000) An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet 9: 259-265.
21. Coovert DD, Le TT, McAndrew PE, Strasswimmer J, Crawford TO, et al. (1997) The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet 6: 1205-1214.
22. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, et al. (1997) Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 16: 265-269.
23. McAndrew PE, Parsons DW, Simard LR, Rochette C, Ray PN, et al. (1997) Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet 60: 1411-1422.
24. Lorson MA, Lorson CL, (2012) SMN-inducing compounds for the treatment of spinal muscular atrophy. Future Med Chem 4: 2067-2084.
25. Passini MA, Cheng SH, (2011) Prospects for the gene therapy of spinal muscular atrophy. Trends Mol Med 17: 259-265.
26. Rigo F, Hua Y, Krainer AR, Bennett CF, (2012) Antisense-based therapy for the treatment of spinal muscular atrophy. J Cell Biol 199: 21-25.
27. Van Meerbeke JP, Sumner CJ, (2011) Progress and promise: the current status of spinal muscular atrophy therapeutics. Discov Med 12: 291-305.
28. Dominguez E, Marais T, Chatauret N, Benkhelifa-Ziyyat S, Duque S, et al. (2011) Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum Mol Genet 20: 681-693.
29. Foust KD, Wang X, McGovern VL, Braun L, Bevan AK, et al. (2010) Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat Biotechnol 28: 271-274.
30. Passini MA, Bu J, Roskelley EM, Richards AM, Sardi SP, et al. (2010) CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J Clin Invest 120: 1253-1264.
31. Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, et al. (2010) Systemic delivery of scAAV9 expressing SMN prolongs survival in a model of spinal muscular atrophy. Sci Transl Med 2: 35ra42.
32. Hua Y, Sahashi K, Rigo F, Hung G, Horev G, et al. (2011) Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model. Nature 478: 123-126.
33. Porensky PN, Mitrpant C, McGovern VL, Bevan AK, Foust KD, et al. (2012) A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet 21: 1625-1638.
34. Avila AM, Burnett BG, Taye AA, Gabanella F, Knight MA, et al. (2007) Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 117: 659-671.
35. Riessland M, Ackermann B, Forster A, Jakubik M, Hauke J, et al. (2010) SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum Mol Genet 19: 1492-1506.
36. Cherry JJ, Evans MC, Ni J, Cuny GD, Glicksman MA, et al. (2012) Identification of novel compounds that increase SMN protein levels using an improved SMN2 reporter cell assay. J Biomol Screen 17: 481-495.
37. Jarecki J, Chen X, Bernardino A, Coovert DD, Whitney M, et al. (2005) Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet 14: 2003-2018.
38. Lunn MR, Root DE, Martino AM, Flaherty SP, Kelley BP, et al. (2004) Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem Biol 11: 1489-1493.
39. Xiao J, Marugan JJ, Zheng W, Titus S, Southall N, et al. (2011) Discovery, synthesis, and biological evaluation of novel SMN protein modulators. J Med Chem 54: 6215-6233.
40. Makhortova NR, Hayhurst M, Cerqueira A, Sinor-Anderson AD, Zhao WN, et al. (2011) A screen for regulators of survival of motor neuron protein levels. Nat Chem Biol 7: 544-552.
41. Singh J, Salcius M, Liu SW, Staker BL, Mishra R, et al. (2008) DcpS as a therapeutic target for spinal muscular atrophy. ACS Chem Biol 3: 711-722.
42. Butchbach ME, Singh J, Thorsteinsdottir M, Saieva L, Slominski E, et al. (2010) Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum Mol Genet 19: 454-467.
43. Gogliotti RG, Cardona H, Singh J, Bail S, Emery C, et al. (2013) The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum Mol Genet.
44. Van Meerbeke JP, Gibbs RM, Plasterer HL, Miao W, Feng Z, et al. (2013) The DcpS inhibitor RG3039 improves motor function in SMA mice. Hum Mol Genet.
45. Gabanella F, Carissimi C, Usiello A, Pellizzoni L, (2005) The activity of the spinal muscular atrophy protein is regulated during development and cellular differentiation. Hum Mol Genet 14: 3629-3642.
46. Grimmler M, Bauer L, Nousiainen M, Korner R, Meister G, et al. (2005) Phosphorylation regulates the activity of the SMN complex during assembly of spliceosomal U snRNPs. EMBO Rep 6: 70-76.
47. Ackermann B, Krober S, Torres-Benito L, Borgmann A, Peters M, et al. (2013) Plastin 3 ameliorates spinal muscular atrophy via delayed axon pruning and improves neuromuscular junction functionality. Hum Mol Genet 22: 1328-1347.
48. Akten B, Kye MJ, Hao le T, Wertz MH, Singh S, et al. (2011) Interaction of survival of motor neuron (SMN) and HuD proteins with mRNA cpg15 rescues motor neuron axonal deficits. Proc Natl Acad Sci U S A 108: 10337-10342.
49. Bowerman M, Beauvais A, Anderson CL, Kothary R, (2010) Rho-kinase inactivation prolongs survival of an intermediate SMA mouse model. Hum Mol Genet 19: 1468-1478.
50. Hao le T, Wolman M, Granato M, Beattie CE, (2012) Survival motor neuron affects plastin 3 protein levels leading to motor defects. J Neurosci 32: 5074-5084.
51. Monani UR, Sendtner M, Coovert DD, Parsons DW, Andreassi C, et al. (2000) The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 9: 333-339.
52. Liu Q, Dreyfuss G, (1996) A novel nuclear structure containing the survival of motor neurons protein. EMBO J 15: 3555-3565.
53. Meister G, Eggert C, Fischer U, (2002) SMN-mediated assembly of RNPs: a complex story. Trends Cell Biol 12: 472-478.
54. Pellizzoni L, Yong J, Dreyfuss G, (2002) Essential role for the SMN complex in the specificity of snRNP assembly. Science 298: 1775-1779.
55. Sumner CJ, Huynh TN, Markowitz JA, Perhac JS, Hill B, et al. (2003) Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 54: 647-654.
56. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, et al. (2003) Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12: 2481-2489.
57. Tsai LK, Tsai MS, Ting CH, Li H, (2008) Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J Mol Med 86: 1243-1254.
58. Hannus S, Buhler D, Romano M, Seraphin B, Fischer U, (2000) The Schizosaccharomyces pombe protein Yab8p and a novel factor, Yip1p, share structural and functional similarity with the spinal muscular atrophy-associated proteins SMN and SIP1. Hum Mol Genet 9: 663-674.
59. Owen N, Doe CL, Mellor J, Davies KE, (2000) Characterization of the Schizosaccharomyces pombe orthologue of the human survival motor neuron (SMN) protein. Hum Mol Genet 9: 675-684.
60. Paushkin S, Charroux B, Abel L, Perkinson RA, Pellizzoni L, et al. (2000) The survival motor neuron protein of Schizosacharomyces pombe. Conservation of survival motor neuron interaction domains in divergent organisms. J Biol Chem 275: 23841-23846.
61. Schrank B, Gotz R, Gunnersen JM, Ure JM, Toyka KV, et al. (1997) Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A 94: 9920-9925.
62. Wang J, Dreyfuss G, (2001) A cell system with targeted disruption of the SMN gene: functional conservation of the SMN protein and dependence of Gemin2 on SMN. The J Biol Chem 276: 9599-9605.
63. Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, et al. (2000) A mouse model for spinal muscular atrophy. Nat Genet 24: 66-70.
64. Winkler C, Eggert C, Gradl D, Meister G, Giegerich M, et al. (2005) Reduced U snRNP assembly causes motor axon degeneration in an animal model for spinal muscular atrophy. Genes Dev 19: 2320-2330.
65. Wishart TM, Huang JP, Murray LM, Lamont DJ, Mutsaers CA, et al. (2010) SMN deficiency disrupts brain development in a mouse model of severe spinal muscular atrophy. Hum Mol Genet 19: 4216-4228.
66. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, et al. (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463-8471.
67. Zufferey R, Dull T, Mandel RJ, Bukovsky A, Quiroz D, et al. (1998) Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 72: 9873-9880.
68. Carissimi C, Baccon J, Straccia M, Chiarella P, Maiolica A, et al. (2005) Unrip is a component of SMN complexes active in snRNP assembly. FEBS Lett 579: 2348-2354.
69. Carissimi C, Saieva L, Gabanella F, Pellizzoni L, (2006) Gemin8 is required for the architecture and function of the survival motor neuron complex. J Biol Chem 281: 37009-37016.